Conducting the G-protein coupled receptor (GPCR) signaling symphony in cardiovascular diseases: New therapeutic approaches

Drug Discovery Today: Disease Models

Volumn 9, Issue 3, 2012, Pages

  Belmonte, Stephen L ^a   Blaxall, Burns C ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ARRESTIN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; LOSARTAN; METOPROLOL; NEBIVOLOL; PINDOLOL; PROPRANOLOL;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BRONCHOSPASM; CARDIOVASCULAR DISEASE; DRUG RECEPTOR BINDING; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE; HUMAN; HYPERTENSION; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

EID: 84871419286     PISSN: None     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2012.03.001     Document Type: Review

References (79)

1. Jacoby, E. et al. (2006) The 7 TM G-protein-coupled receptor target family. ChemMedChem 1, 761-782
2. Flower, D.R. (1999) Modelling G-protein-coupled receptors for drug design. Biochim. Biophys. Acta 1422, 207-234
3. Salon, J.A. et al. (2011) The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol. Rev. 63, 901-937
4. Feldman, R.D. (1990) Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. J. Clin. Invest. 85, 647-652
5. Bristow, M.R. et al. (1982) Decreased catecholamine sensitivity and betaadrenergic- receptor density in failing human hearts. N. Engl. J. Med. 307, 205-211
6. Ungerer, M. et al. (1993) Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 87, 454-463
7. Meij, J.T. (1996) Regulation of G protein function: implications for heart disease. Mol. Cell. Biochem. 157, 31-38
8. Liggett, S.B. (2011) Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci. Signal. 4, pe36
9. Luttrell, L.M. and Kenakin, T.P. (2011) Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol. Biol. 756, 3-35
10. Patel, C.B. et al. (2010) Functional selectivity in adrenergic and angiotensin signaling systems. Mol. Pharmacol. 78, 983-992
11. Tang, C.M. and Insel, P.A. (2004) GPCR expression in the heart; new receptors in myocytes and fibroblasts. Trends Cardiovasc. Med. 14, 94-99
12. Lagerstrom, M.C. and Schioth, H.B. (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339-357
13. Frishman, W.H. (2008) beta-Adrenergic blockers: a 50-year historical perspective. Am. J. Ther. 15, 565-576
14. Brodde, O.E. (1993) Beta-adrenoceptors in cardiac disease. Pharmacol. Ther. 60, 405-430
15. Feldman, D.S. et al. (2005) Mechanisms of disease: beta-adrenergic receptors - alterations in signal transduction and pharmacogenomics in heart failure. Nat. Clin. Pract. Cardiovasc. Med. 2, 475-483
16. Guimaraes, S. and Moura, D. (2001) Vascular adrenoceptors: an update. Pharmacol. Rev. 53, 319-356
17. Dessy, C. and Balligand, J.L. (2010) Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv. Pharmacol. 59, 135-163
18. Triposkiadis, F. et al. (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54, 1747-1762
19. Talan, M.I. et al. (2011) beta AR agonists in treatment of chronic heart failure: long path to translation. J. Mol. Cell. Cardiol. 51, 529-533
20. Gauthier, C. et al. (2011) Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies. Curr. Heart Fail. Rep. 8, 184-192
21. Kang, M. et al. (2007) G-protein coupled receptor signaling in myocardium: not for the faint of heart. Physiology (Bethesda) 22, 174-184
22. Bristow, M.R. et al. (1990) Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82 (Suppl.), I12-I25
23. Belmonte, S.L. and Blaxall, B.C. (2011) G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ. Res. 109, 309-319
24. Casey, L.M. et al. (2010) Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ. Res. 107, 532-539
25. Kamal, F.A. et al. (2011) Taking the heart failure battle inside the cell: Small molecule targeting of Gbg subunits. J Mol Cell Cardiol 51, 462-467
26. Brinks, H. and Koch, W.J. (2010) betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease. J. Cardiovasc. Transl. Res. 3, 499-506
27. Rengo, G. et al. (2011) GRK2 as a novel gene therapy target in heart failure. J. Mol. Cell. Cardiol. 50, 785-792
28. Ferguson, S.S. (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1-24
29. Lefkowitz, R.J. and Shenoy, S.K. (2005) Transduction of receptor signals by beta-arrestins. Science 308, 512-517
30. DeWire, S.M. et al. (2007) Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510
31. Tilley, D.G. et al. (2009) beta-Arrestin mediates beta1-adrenergic receptorepidermal growth factor receptor interaction and downstream signaling. J. Biol. Chem. 284, 20375-20386
32. Noma, T. et al. (2007) Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445-2458
33. Noor, N. et al. (2010) Beta-arrestin: a signaling molecule and potential therapeutic target for heart failure. J. Mol. Cell. Cardiol. 51, 534-541
34. Reiner, S. et al. (2010) Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J. Biol. Chem. 285, 36188-36198
35. Drake, M.T. et al. (2008) beta-arrestin-biased agonism at the beta2- adrenergic receptor. J. Biol. Chem. 283, 5669-5676
36. Rakesh, K. et al. (2010) beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci. Signal. 3, ra46
37. Kim, J. et al. (2005) Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 102, 1442-1447
38. DeWire, S.M. and Violin, J.D. (2011) Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ. Res. 109, 205-216
39. Tangeman, H.J. and Patterson, J.H. (2003) Extended-release metoprolol succinate in chronic heart failure. Ann. Pharmacother. 37, 701-710
40. Janosi, A. et al. (2003) Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am. Heart. J. 146, 721-728
41. Kim, I.M. et al. (2008) Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc. Natl. Acad. Sci. U.S.A. 105, 14555-14560
42. Wisler, J.W. et al. (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 104, 16657-16662
43. Ruffolo, R.R., Jr et al. (1990) The pharmacology of carvedilol. Eur. J. Clin. Pharmacol. 38 (Suppl. 2), S82-S88
44. Dinicolantonio, J.J. and Hackam, D.G. (2012) Carvedilol: a thirdgeneration beta-blocker should be a first-choice beta-blocker. Expert Rev. Cardiovasc. Ther. 10, 13-25
45. Zablocki, D. and Sadoshima, J. (2011) Knocking out angiotensin II in the heart. Curr. Hypertens. Rep. 13, 129-135
46. Porsti, I. et al. (1993) Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart. Naunyn Schmiedebergs Arch. Pharmacol. 348, 650-658
47. Baker, K.M. et al. (1984) Identification and characterization of the rabbit angiotensin II myocardial receptor. Circ. Res. 54, 286-293
48. Wright, G.B. et al. (1983) Characterization of the rabbit ventricular myocardial receptor for angiotensin. II. Evidence for two sites of different affinities and specificities. Mol. Pharmacol. 24, 213-221
49. Sadoshima, J. and Izumo, S. (1993) Molecular characterization of angiotensin II - induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ. Res. 73, 413-423
50. Saito, S. et al. (1996) Angiotensin II activates endothelial constitutive nitric oxide synthase via AT1 receptors. Hypertens. Res. 19, 201-206
51. Castro-Chaves, P. et al. (2009) Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart. Exp. Physiol. 94, 665-674
52. Schmermund, A. et al. (1999) Cardiac production of angiotensin II and its pharmacologic inhibition: effects on the coronary circulation. Mayo Clin. Proc. 74, 503-513
53. Sasaki, K. et al. (1991) Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351, 230-233
54. Murphy, T.J. et al. (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351, 233-236
55. Mukoyama, M. et al. (1993) Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 268, 24539-24542
56. Mehta, P.K. and Griendling, K.K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82-C97
57. Ushio-Fukai, M. et al. (1998) Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J. Biol. Chem. 273, 19772-19777
58. Nishizuka, Y. (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607-614
59. Crabos, M. et al. (1994) Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J. Clin. Invest. 93, 2372-2378
60. Baker, K.M. and Singer, H.A. (1988) Identification and characterization of guinea pig angiotensin II ventricular and atrial receptors: coupling to inositol phosphate production. Circ. Res. 62, 896-904
61. Baker, K.M. et al. (1992) Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu. Rev. Physiol. 54, 227-241
62. Yusuf, S. et al. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153
63. Julius, S. (1990) Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension. J. Cardiovasc. Pharmacol. 15 (Suppl. 5), S53-S58
64. Tan, L.B. et al. (1991) Cardiac myocyte necrosis induced by angiotensin II. Circ. Res. 69, 1185-1195
65. Kim, S. et al. (1995) Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25, 1252-1259
66. Rockman, H.A. et al. (1994) Ang II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am. J. Physiol. 266 (Pt 2), H2468-H2475
67. Weinberg, E.O. et al. (1994) Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90, 1410-1422
68. Pfeffer, M.A. et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327, 669-677
69. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316, 1429-1435
70. Iusuf, D. et al. (2008) Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur. J. Pharmacol. 585, 303-312
71. Holloway, A.C. et al. (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol. Pharmacol. 61, 768-777
72. Wei, H. et al. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 100, 10782-10787
73. Aplin, M. et al. (2007) The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin. Pharmacol. Toxicol. 100, 289-295
74. Violin, J.D. et al. (2010) Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335, 572-579
75. Boerrigter, G. et al. (2010) Cardiorenal actions of TRV120027, a novel ssarrestin- biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ. Heart Fail. 4, 770-778
76. Brinks, H. and Koch, W.J. (2010) Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure. Drug Discov. Today Dis. Mech. 7, e129-e134
77. Barki-Harrington, L. et al. (2003) Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108, 1611-1618
78. Jaffre, F. et al. (2009) Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ. Res. 104, 113-123
79. Goldsmith, S.R. (2004) Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr. Heart Fail. Rep. 1, 45-50